Atopic Dermatitis MSD PEd Point of View_dr. Nia
-
Upload
kgs-mahendra-effendy-ii -
Category
Documents
-
view
222 -
download
0
description
Transcript of Atopic Dermatitis MSD PEd Point of View_dr. Nia
![Page 1: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/1.jpg)
Nia Kurniati
![Page 2: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/2.jpg)
• Pediatrician encounter 1 out of 10-15 patient with skin problems in OPD
• Generally they understand how to diagnose and deliver basic management
• There are many things that is not direct
![Page 3: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/3.jpg)
• Related to “Atopic March”: § As first step
• Around 75-80% will develop allergic rhinitis in later life
• Around 50% will develop asthma
Leung, JACI 2003 (Suppl): S117
![Page 4: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/4.jpg)
Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1491.
![Page 5: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/5.jpg)
![Page 6: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/6.jpg)
ADULT
12 > y.o - adult
CHILDHOOD
2-12 y.o
INFANTILE baby- 2
y.o.
![Page 7: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/7.jpg)
![Page 8: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/8.jpg)
![Page 9: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/9.jpg)
• more dry lesion • more chronic itch scratch lichenification • Recurrence acute erythema, plaque
infiltrate, papules dan erosion • Location in hand, feet, wrist & ankle • Lesion in flexural antecubital & popliteal main sign
![Page 10: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/10.jpg)
![Page 11: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/11.jpg)
William Criteria
Basic feature (obligatory) • Itchy skin
• Skin symptoms in flexural regions & neck (cheeks in children < 10 years)
• Asthma / allergic rhinitis (or atopic diseases in close relatives in children < 4 years)
• Dry skin during the last years • Visible eczema in flexural areas (or on cheeks and/or
forehead in chlidren < 4 years) • Eczema starting before age 2
Additional features
Diagnosis : Itchy skin + minimal 3 of the additional features
![Page 12: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/12.jpg)
ASSESING DISEASE SEVERITY
![Page 13: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/13.jpg)
• Developed by ETFAD on 1993
• Maximum score is 103
•0-34 MILD
•35
-69 MODERATE
•70
-103
SEVERE
Pediatrician do not practice this
![Page 14: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/14.jpg)
Modified Qualitative Scoring for AD – Developed by Prof. Thiru THIRUMOORTHY
Classification of Severity in the Clinic to guide the Intensity of Treatment required
Episodic Localised Flexural (2 or less flexures)
Episodic Extensive Flexural
Persistent Extensive Flexural
Persistent Extensive Flexural & Non-flexural
Generalised Atopic dermatitis – childhood
Generalised Atopic dermatitis – adulthood
Redness – None, Mild, Moderate, Severe Swelling(edema) – None, Mild, Moderate, Severe Oozing / crusting – None, Mild, Moderate, Severe Scratch marks(excoriation) – None, Scattered, Disseminated, Severe Skin thickening (lichenification) None, Mild, Moderate, Severe
Asses the most dominant sign found
None=0; Mild=1; Moderate=2; Severe=3
![Page 15: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/15.jpg)
• Clinical impression of the extend of the lesion • Recurrent and persistent lesion
![Page 16: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/16.jpg)
![Page 17: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/17.jpg)
Standard Treatment: skin hydration, emollient, avoid irritant, identify and
avoid aggravating factor
Systemic Therapy (e.g: Cyclosporin A) or UV therapy
TCS moderate-super potent and/or TCI
TCS mild-moderate and/or TCI
DA severe,recalsitran
DA moderate-severe
DA mild - moderate
Dry Skin Only
4
3
2
1
TCS: topical corticosteroid ; TCI: topical calcineurin inhibitor
![Page 18: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/18.jpg)
1. Education and empowerment of patients and caregiver(s) 1. Eczema school/eczema camps
2. Avoidance and modification of environmental trigger factors 1. Lifestyle modification 2. Avoidance of skin injury 3. Rebuilding and maintenance of optimal barrier
function 4. Clearance of inflammatory skin disorders 5. Control and elimination of the itch–scratch cycle
Rubel D, et al. Consensu guideline for the management of Atopic Dermatitis: An
![Page 19: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/19.jpg)
Asia-Pacific perspectives. J Dermatol 2013;40:161-70
Recognize trigger factors Use of standardize lists ( house dust mite,
chemical substance, 5 food)
Clearance of inflammatory skin disorders Use of Topical Corticosteroid (TCS)
Control and elimination of the itch–scratch cycle Oral antihistamine
![Page 20: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/20.jpg)
1. Education and empowerment of patients and caregiver(s)
2. Avoidance and modification of environmental trigger factors
1. Lifestyle modification
2. Avoidance of skin injury
3. Rebuilding and maintenance of optimal barrier function
4. Clearance of inflammatory skin disorders
5. Control and elimination of the itch–scratch cycle
![Page 21: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/21.jpg)
It could be an easy or hardest part History taking---taking time
Allergy tests --- are not in straight causal relationship (positive result doesn’t translate as the cause of AD, negative result is often misleading)
The patient (and family) should have discipline to avoid trigger factors Develop a relationship with the family
![Page 22: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/22.jpg)
Severity of
AD
Inhalant and/or food allergen
Food allergen only
Mild 15% 20%
Moderate 18% 26%
Severe 20% 45%
Patrizi A, et al. The natural history of sensitizations to food and aeroallergens in atopic dermatitis: a 4-year follow up, Pediatr Dermatol 2000;17:261-5
![Page 23: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/23.jpg)
Severity of AD Inhalant and/or food allergen
Food allergen only
Asthma and/ or allergic rhinitis
Mild 31% 6% 15%
Moderate 52% 6% 32%
Severe 100% 0% 75% Patrizi A, et al. The natural history of sensitizations to food and aeroallergens in atopic dermatitis: a 4-year follow up, Pediatr Dermatol 2000;17:261-5
![Page 24: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/24.jpg)
![Page 25: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/25.jpg)
Topical Corticosteroid, Topical Calcineurin, systemic
The wise ways to choose corticosteroid
Correct indication and know the contraindication Choose the appropriate potency
Minimal side effects
Acceptability
Cost and benefit
![Page 26: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/26.jpg)
![Page 27: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/27.jpg)
C27H30Cl2O6
9α,21-dichloro-11β, 17 α -dihydroxy-16 α -methylpregna- 1,4 diene-3,20 dione 17-(2- furoate) 1 http:/ / www.chemspider.com/ ImageView.aspx?mode=3d&id=390091
![Page 28: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/28.jpg)
27
Need to address concerns regarding steroid phobia
If used correctly, AEs such as suppression of adrenal function, diabetes mellitus, and moon face
Low potential for skin atrophy with mometasone and fluticasone in children/adults
1 Hanifin J, et al. Br J Dermatol 2002;147:528-537; 2Berth-Jones J, et al. BMJ 2003;326:1367.3Hong E, et al. Pediatr Dermatol 2011;28:393-396; 4Saeki H, et al. J Dermatol 2009;36:563-577.
![Page 29: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/29.jpg)
• Acute• Chronic (maintenance): intermittent, week end, hot
spot, has proven to control inflammation in recalcitrant cases
![Page 30: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/30.jpg)
A number of defects in innate cutaneous immunology may explain the high rate of cutaneous
colonization with Staphylococcus aureus in AD
![Page 31: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/31.jpg)
• This led to the clinical concept that patients with high numbers of colonizing S. aureus can benefit
from combination treatment with corticosteroids and antimicrobial treatment (Diprogenta®)
Improving eczema with anti-inflammatory regimen decreases staphyloccocal colonization.
![Page 32: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/32.jpg)
![Page 33: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/33.jpg)
TCIs=topical calcineurin inhibitors; TCS=topical corticosteroids
Journal of Dermatology 2013; 40: 160–171
![Page 34: Atopic Dermatitis MSD PEd Point of View_dr. Nia](https://reader031.fdocuments.net/reader031/viewer/2022032005/563dbaff550346aa9aa9645b/html5/thumbnails/34.jpg)
• Atopic Dermatitis is an important step in allergic march in children
• Stepwise management also apply in children, with emphasis on triggering factors management